Could Ozempic, Wegovy, Trulicity, Mounjaro and Reybelsus Cause Adverse Gastrointestinal Injury?

In recent years, GLP-1 receptor agonists such as Ozempic, Wegovy, Trulicity, Mounjaro and Reybelsus have gained popularity as treatments for type 2 diabetes and obesity. While they have been effective for many patients in managing blood sugar levels and weight, concerns have arisen about potential adverse gastrointestinal injuries linked to these medications. Understanding how these… Continue reading